Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05757102 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

StatusRecruiting
PhasePhase 3
Started2023-04-25
View on ClinicalTrials.gov ↗
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Amendment record

Amended 7 times since 2023-02-24; most recent filed 2026-07-15. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-07-15
Amendment Study Status, Contacts/Locations v7
2025-10-06
Amendment Study Status, Contacts/Locations v6
2025-06-04
Amendment Study Status, Contacts/Locations v5
2025-05-28
Amendment Study Status, Contacts/Locations v4
2024-05-24
Amendment Study Status, Contacts/Locations v3
2024-01-05
Amendment Study Status v2
2023-07-21
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2023-02-24
Original filing
Trial Details
NCT Number NCT05757102
Lead Sponsor GlaxoSmithKline
Conditions Asthma
Enrollment 292 participants
Start Date 2023-04-25
Primary Completion 2027-01-22 (estimated)
Study Completion 2027-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-16